Novartis has selected PharmaVentures as advisors to address options for its UK Horsham site. In February, Novartis announced plans to close the Horsham site following a global review of its research operations.
 
Options for the site could include reusing part of the site as a science or business park. PharmaVentures will provide advice on this possibility and will help identify potential partners.
 
Dr. Fintan Walton, chief executive officer of PharmaVentures, said, “The Novartis Horsham site is a perfect location for a high technology park. Novartis has built state of the art facilities, suitable for pharmaceutical / life science or other high technology businesses. With such high quality facilities, we expect interest from both universities and research institutes. The site would also be ideal as a business park as Horsham is an attractive location due to its strong international links through Gatwick airport and its proximity to London.”